Day 1 at ASGCT: Missing scientists, a gene editing failure, and a gene editing first
The annual meeting of the American Society of Cell and Gene Therapy in New Orleans had a mixed atmosphere. Despite the challenges facing the biotech market and uncertainties surrounding the FDA and NIH, there was a sense of optimism among researchers in attendance. The event saw the approval of 16 gene and cell therapies over the past four years, highlighting the progress in the field.
One quirky highlight of the conference was a purple-clad Mardi Gras-style stilt walker welcoming attendees into the main hall, adding a festive touch to the event. However, amidst the buzz of the conference, there were some notable absences. Several prominent scientists were unable to attend, citing issues related to various policies under the Trump administration.
As the conference unfolded, discussions centered around the latest advancements in cell and gene therapy research. While some researchers projected confidence in the future of the field, there was a sense of concern lingering in the background. The ongoing challenges facing the biotech industry and regulatory uncertainties cast a shadow over the otherwise hopeful atmosphere of the event.
Despite the hurdles, the researchers, advocates, and executives present at the ASGCT meeting remained committed to advancing the field of cell and gene therapy. The conference provided a platform for sharing groundbreaking research, fostering collaborations, and exploring new possibilities in the realm of genetic medicine.
Stay tuned for more updates from the conference on Thursday and Friday, where more insights and developments are expected to be unveiled. The ASGCT meeting serves as a crucial gathering for the scientific community to exchange ideas, showcase innovations, and chart the course for the future of cell and gene therapy. Let’s look forward to more exciting discoveries and advancements in this rapidly evolving field.
